Search results

Background: This paper examines the relationship between determinants of blood transfusion sustainability (BTS) that is master production scheduling (MPS) and blood production (BP) of Uganda. The study was founded on four objectives. The study looked at the direct relationship between MPS and the BTS, direct relationship between MPS and BP, direct relationship between BP and BTS. It also assessed how BP mediated the direct relationship between MPS and BTS. The study used a quantitative method.

Methods: A survey questionnaire was administered to collect data from 367 staff of regional blood banks and government university teaching hospital blood banks; and 213 were found to be usable. The main analysis was done using structural equation modeling.

Results: This study found that MPS had a negative and insignificant relationship with the BTS. The study found that relationship between MPS and BP was positive and significant. The study also found that relationship between BP and BTS was positive and significant. The study concluded that the effect of MPS on BTS was fully mediated by BP. It was recommended that blood banks seeking to achieve transfusion sustainability must understand the sector in which they operate. The various stakeholders in the blood supply chain ie blood banks, hospital blood banks, funding agents, ministry of health, must also integrate to enhance the transfusion sustainability. Blood banks performance measures essentially timely delivery was very critical for saving lives of patients in need of blood.

Conclusion: The study has provided a new conceptual framework that investigate the BP mediating effect on the relationship of MPS and BTS, and thus can serve as an incentive for more research to be conducted in this regard of different developing countries. The authors also proposed identifying the effect of other BP factors such as blood donor management and hospital transfusion practices on BTS.

Three years after a consensus development conference on blood transfusion policy in the Netherlands, its effect on the quality of care was evaluated. In 16 out of 22 bloodbanks and 66 per cent of the hospitals the consensus text had been discussed and used as a basis for the formulation or modification of guidelines. In 17 (nine per cent) hospitals a formal quality assurance study had been performed: In 11 change was found to be necessary; a re‐evaluation, performed in seven, showed improvement of transformation policy in five. In all studies the criteria used were in agreement with the statements of the consensus text.

The overall aim of the research presented is to improve blood supply chain management in order to use the scarce resource of blood more efficiently. Computer simulation is used as a tool for increasing efficiency in blood supply chains.

An application of discrete event simulation modeling in the health‐care sector, more specifically in the area of blood transfusion services. The model has been refined in cooperation with medical expertise as it is vital that practitioners are closely involved so that the model can be tested against their understanding as it develops.

Decision makers can make better and less risky decisions regarding changes in the blood supply chain based on the knowledge created by simulation experiments. Simulation modeling can be used to make complex and chaotic systems comprehensible and more efficient. In health care, this means that scarce resources can be allocated better, and thereby simulation can aid in increasing the overall quality of health care.

Models are simplifications and there is no guarantee that they will be valid, however, when used sensibly, simulation models and modeling approaches provide an important tool to managing risk and uncertainty in health care supply chains.

Earlier calculations and improvement efforts of blood supply chain in focus were based on “gut feeling”. Through applying simulation to this complex system, the dynamics of blood supply chain was more easily understood by the medical expertise.

There is a lack of work on computer simulations of blood supply chains, a challenge which this work has taken up on.

Blood cold chain (BCC) represents a system for preserving the blood during its journey from the donor to the ultimate transfusion site. Existing BCCs have many drawbacks related to information transparency and information security. Secured and real-time information sharing in BCC can bring several benefits. The purpose of this paper is to summarise the issues in typical BCCs and to explore the scope of blockchain in the management of BCCs.

Issues in the existing BCCs are identified through a narrative review. To explain the potential of blockchain in mitigating these issues, a blockchain-based traceability solution is demonstrated with respect to a particular BCC scenario. The BCC management system discussed in this study makes use of the Ethereum blockchain’s smart contract feature and internet of things (IoT) technology. The smart contract is written in the solidity programming language and tested and validated using the Remix integrated development environment.

BCCs are concerned with several issues both from technical and non-technical perspectives. Blockchain technology is capable of troubleshooting the issues in the existing BCCs. Combining blockchain and IoT technology enables real-time information sharing among the entities. The demonstration presented in this work depicts how the blockchain-based smart contract can support operations in a typical BCC.

This paper explores the scope of blockchain in BCCs through a demonstration. To get insights into its technical and economical feasibilities, further investigations are needed.

Blockchain-based traceability system presented in this work can be adopted in BCCs to ensure the quality of blood or blood products. Blockchain-based smart contracts can aid the BCCs to achieve a proper balance between blood shortage and outdating.

Maintaining a safe and available supply of blood requires a mindfully coordinated supply chain (SC) and is fundamental to the effective operation of health systems across the world. This study investigates how blood supply chain (BSC) actors demonstrate collective mindfulness (CM) principles in their operations and how these demonstrations lead to improvements in blood safety and availability (BSA) in different operational contexts.

Six case studies drawn from two contrasting BSCs, the UK and Indonesia, which differ in structure and regulation are investigated in this research. Qualitative data are collected and analysed using template analysis.

The cases reveal how the CM principles are demonstrated in the supply chain context in a range of operational conditions and their impact on BSA. The BSC actors in the more centralised and tightly regulated cases display more behaviours consistent with more of the CM principles over a greater range of operational conditions compared to those in the more decentralised and loosely regulated cases. As such, more improvements in BSA are found in the former compared to the latter cases.

This paper is considered the first to investigate the demonstration of CM principles at the SC as opposed to the single organisational level. It proposes an alternative approach to understanding and evaluating reliability performance using behavioural rather than statistical principles.

The purpose of this paper is to develop a generic framework for the assessment of VMI implementation. The framework is used for the analysis of multiple case studies in German hospitals to discuss the feasibility of VMI in the German blood supply chain.

The methodology is twofold. In a first step, the literature is reviewed and a generic theoretical VMI framework is developed. In a second step, the case study methodology is applied to 13 cases to assess the feasibility of VMI in the German blood supply chain.

The paper contributes a generic framework for assessing the implementation of VMI in seven steps. The research proposed that hospitals hesitate to enter a VMI relationship for critical resources such as blood. Hospitals fear losing control over critical resources.

The unit of analysis is hospitals in Germany and the case studies do not target the suppliers in the supply chain. The paper contributes three propositions regarding VMI in the healthcare/blood supply chain.

A generic framework for assessing the applicability and feasibility of VMI is provided which supports managers with the implementation of VMI in a supply chain.

The paper is one of the first papers targeting inventory and supply chain management in the German blood supply chain. It provides a generic framework for the assessment of the feasibility of VMI.

Blood banking involves the collection of blood from donors and the storage of that blood until it is required for transfusion. It is usual to distinguish, in a blood banking system, between central blood banks whose functions are primarily those of collection and distribution, and hospital blood banks which perform the process of cross‐matching. In order to ensure that the donor's blood will be compatible with that of the recipient, blood is cross‐matched by mixing a sample of the recipient's blood with a sample of stored blood of the same group and subjecting the mixture to certain tests.

The US platelet supply is almost exclusively dependent on apheresis donors who are “aging out.” As a result, blood centers and hospitals have been experiencing spot shortages and have resorted to transfusing low-dose platelets. This paper explores using whole blood–derived platelets (WB-PLTs) to supplement the apheresis platelet (APH-PLT) supply.

This paper reviews the history leading to the current state of the US platelet supply and includes the impact of recent events such as the COVID-19 pandemic and the implementation of the US Food and Drug Administration (FDA)-mandated bacterial mitigation strategies.

WB-PLTs represent a viable source of platelets that can be used to supplement the APH-PLT supply. Whole blood automation represents a new methodology to more easily prepare WB-PLTs. Advances in donor testing and screening as well as pre-storage leukoreduction have improved the safety of WB-PLTs to the same level as APH-PLTs. Blood services in the US and abroad transfuse WB-PLTs interchangeably in all patient populations.

This paper highlights how the US blood industry is essentially “sole-sourced” in terms of APH-PLTs. In this post-COVID-19 period, when most industries are building redundancies in their supply chains, blood centers should consider WB-PLTs as an additional source of platelets to bolster the US platelet supply.

The aim of this paper is to motivate blood donation among international students and demonstrate the applicability of marketing techniques in the health care sector.

The paper uses a combination of focus groups and a questionnaire‐based survey.

The paper finds that donors primarily find gratification from their altruistic acts through awareness of their contribution to saving lives. Receiving information on how each individual donation is used is seen as a powerful means of reinforcement. Practical benefits such as receiving free blood test information are also useful motivators, while communicating the professionalism of the blood collection techniques are important for reassuring the minority of prospective donors who expressed fears about possible risks associated with blood donation.

Since this was a small‐scale study among Hungarian and international students in Budapest, further research is necessary to validate its results among other demographic groups.

Findings were reported to the International Federation of Red Cross and Red Crescent Societies in Hungary in order to increase blood donations among students in Hungary. Subject to validation through further research, applying recommended approaches in different countries and other demographic groups is suggested.

This is the first research paper on motivation toward blood donation among international students and offers new and practical suggestions for increasing their level of participation in blood drives.